转移性前列腺癌的核素显像检查与核素治疗进展  

The radionuclide imaging and therapy for metastatic prostate cancer

作　　者：何雪心[1] 周金云 李浩然 金晨涛 田梅[2] He Xuexin;Zhou Jinyun;Li Haoran;Jin Chentao;Tian Mei(Department of Medical Oncology,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Nuclear Medicine,The Second Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou 310009,China;Department of Urology,Huntsman Cancer Institute,University of Utah,Salt Lake City 84101,USA)

机构地区：[1]浙江大学医学院附属第二医院肿瘤内科,杭州310009 [2]浙江大学医学院附属第二医院核医学科,杭州310009 [3]犹他大学癌症中心泌尿内科,美国盐湖城84101

出　　处：《中华泌尿外科杂志》2021年第10期792-796,共5页Chinese Journal of Urology

摘　　要：转移性前列腺癌是威胁男性健康的主要恶性肿瘤之一。^(68)镓(^(68)Ga)或^(18)氟(^(18)F)标记的前列腺特异性膜抗原(PSMA)正电子发射断层显像/计算机断层显像(PET/CT)对转移性前列腺癌的诊断、临床决策指导、疗效监测及预后评估等具有独特价值。^(223)镭(^(223)Ra)和^(177)镥(^(177)Lu)-PSMA放射性配体治疗(RLT)可有效缓解转移性前列腺癌患者的骨痛,延长其总生存时间和无进展生存期,同时具有良好的安全性。此外,PSMA RLT联合雄激素剥夺治疗、化疗、靶向治疗或免疫治疗将有望进一步改善转移性前列腺癌患者的生存。Metastatic prostate cancer is one of the most malignancies and do harm to the health and life expectancy of men.The popularization and application of ^(68)Gallium or ^(18)Fluorine labeled prostate-specific membrane antigen(PSMA)positron emission tomography/computed tomography(PET/CT)benefit for the excellent diagnostic efficacy,unique value in the diagnosis of metastatic prostate cancer,clinical decision-making guidance,efficacy in monitoring and prognosis evaluation.^(223)Radium and ^(177)Lu-PSMA radioligand therapy(RLT)could effectively alleviate bone pain,and prolong the overall survival time(OS)as wellas progression-free survival time(PFS)with good safety.In addition,survival of patients with metastatic prostate cancer is expected to be further improved with the advance in the combination therapies with PSMA RLT,androgen-deprivation therapy(ADT),chemotherapy,targeted therapy and immunotherapy.

关 键 词：前列腺肿瘤 转移性前列腺癌 前列腺特异性膜抗原 放射性配体治疗 核素显像 核素治疗 

分 类 号：R737.25[医药卫生—肿瘤]